SHOX2 (SHOX Homeobox 2)

Bioinformatics analysis demonstrated high PLK2 expression was positively associated with oncogenes such as FAM163A, CTNND2, DAAM2, PITX1, POU1F1, mir-196a and negatively associated with tumor suppressors such as EMX2, PADI3, CDO1, SHOX2 and mir-508. In conclusion, the research elaborates on the expression profile and the clinical significance of PLK2 gene in AML, suggesting PLK2 expression may help risk stratification and hypothesis-generating for HSCT decision support.

DNA methylation and microRNA biomarkers hold strong promises for non-invasive CRC screening. Multi-marker panels demonstrate superior diagnostic accuracy and may provide a cost-effective, scalable approach for early CRC detection in resource-limited settings.

Cytological examination combined with methylation detection can greatly improve the diagnosis rate of malignant ascites. The methylation status of SHOX2 and SEPTIN9 genes is significantly correlated with the prognosis of patients with ascites.

Abnormal methylation of SHOX2, CDO1, and SOX17 is prevalent in lung cancer, potentially serving as biomarkers for early diagnosis and prognostic monitoring.

Integrating methylation markers SHOX2, HOXA9, Septin9, and RASSF1A exhibits significant diagnostic potential in pleural effusion lymphoma, especially within DLBCL subgroups. These markers could prove valuable in identifying high-risk subgroups and guiding clinical decision-making.

No significant correlation was observed between the methylation of SHOX2/RASSF1A and clinicopathological characteristics, regardless of sex, age, tumor differentiation degree, TNM stage, or nodal status. These findings suggest that the combined detection of SHOX2 and RASSF1A methylation has a potential diagnostic value for early-stage LUAD.

In addition to the kinetic and MAP pathways, docking analysis confirmed that S. platensis binds with the highest affinity to the predicted active sites of the tumor receptor IL-F3, thereby validating its antitumor activity. In conclusion, great suppression in the virulence of lung cancer was reported following treatment with S. platensis, illustrating its suspected mechanism of action, safety profile, kinetic properties, molecular docking results, toxicity, and internal pathways.

This two-round EQA study in China emphasizes the need for improvement in the performance of mSHOX2 and mRASSF1A methylation detection. These results underscore the critical role of EQA schemes in monitoring and improving the detection quality in clinical laboratories. To address the challenges in mSHOX2 and mRASSF1A detection, targeted recommendations are proposed to enhance detection accuracy and reliability.

This study demonstrates combining imaging with cfDNA methylation and 7-AABs enhances preoperative risk stratification. These biomarkers also show promise for evaluating treatment response and guiding surveillance, supporting their use in precise lung cancer management.

The accuracy of the model was significantly higher than the individual biomarkers. These results demonstrated that this panel based on four methylation markers and cfDNA concentration was effective in lung cancer detection, and may provide clinical utility in combination with current lung cancer detection techniques to improve the diagnosis of lung cancer.

In patients with pulmonary tuberculosis, the combined methylation detection showed 75.0% sensitivity in diagnosing tuberculosis complicated with lung cancer. In conclusion, methylation detection in percutaneous lung biopsy preservation fluid, when combined with traditional pathology, can effectively reduce missed diagnoses and is worthy of further promotion.

The combined analysis of SHOX2 and RASSF1A methylation demonstrated promising diagnostic accuracy for MPE detection, outperforming cytology. This less invasive method could reduce reliance on more invasive procedures, although further research is needed to confirm its efficacy across diverse populations and cancer types.